CJC-1295 + Ipamorelin Stack Research Guide 2026

The CJC-1295 and Ipamorelin combination has become the default GH-axis research stack because its mechanistic rationale is unusually clear: two compounds, two receptors, same downstream output. Understanding why that works requires understanding what each compound does independently and why combining them is more than additive.

CJC-1295 — GHRH Receptor Activation

CJC-1295 is a modified GHRH analog that activates the GHRH receptor on pituitary somatotroph cells, increasing cyclic AMP and triggering GH synthesis and release. The DAC-modified version binds albumin for extended half-life; the non-DAC version has a shorter window more similar to native GHRH. Either way, the mechanism is GHRH receptor-mediated — the pituitary is being stimulated through its native GH release pathway.

Ipamorelin — Ghrelin Receptor Activation

Ipamorelin is a GHRP (growth hormone releasing peptide) that activates the ghrelin receptor (GHS-R1a), a completely separate receptor from the GHRH receptor CJC-1295 targets. Ghrelin receptor activation also stimulates GH release from somatotrophs, but through a distinct intracellular signaling cascade — and importantly, without the cortisol or prolactin elevation associated with earlier GHRPs like GHRP-6.

Why the Combination Is Studied Together

When GHRH and ghrelin receptor signaling are activated simultaneously, research models have documented a synergistic rather than merely additive effect on GH pulse magnitude — the combined GH release is larger than the sum of what each compound produces independently. The proposed mechanism is convergent signaling in the somatotroph: two distinct pathways arriving at the same output simultaneously produce a larger response than either pathway activated alone.

Research Use Only. DisclaimerFor laboratory and research use only. Not for human consumption. This content is educational and does not constitute medical advice.